ISPOR Europe 2022 Home
  • Program
    • Program
      • Session
      • Paper
    • Learning Formats
    • Plenary Sessions
    • Spotlight Sessions
    • Posters
    • Educational Symposia & HEOR Theater
    • Program Committee
    • Speaker & Poster Presenter Resources
    • Student Program
large-circle

ISPOR Europe 2022

6 - 9 November

  • Home
  • Events
  • Past Conferences
  • Program
  • Program
  • Session

  • Lorlatinib As a First-Line Treatment for Alk+ Advanced Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis in Spain

    Nov 7, 2022, 15:00 PM
  • «
  • 1621
  • 1622
  • 1623
  • 1624 (current)
  • 1625
  • 1626
  • 1627
  • 1628
  • 1629
  • 1630
  • »
Quick Links
  • About
  • Media Center
  • Exhibits & Sponsorships
  • Contact Us
Policies & Legal
  • Antitrust Compliance
  • Code of Ethics
  • Cookie Policy
  • Diversity Policy
  • Funding Statement
  • Legal Disclaimer
  • Privacy Policy
  • Terms and Conditions

Subscribe

Join ISPOR

ISPOR–The Professional Society for
Health Economics and Outcomes Research

Copyright © 2018 ISPOR. All rights reserved.

International Society for Pharmacoeconomics and Outcomes Research, Inc

Website Design & Development by Matrix Group